Yamamoto Masahiro

Affiliation and department：
Job title： Professor

Research field (1)： Experimental pathology

Research theme for competitive and other funds (7)：

2020 - 2023 Sleeping Beautyマウス肝発がんモデルを用いた新規肝がん治療薬の開発
2017 - 2019 マウス肝癌モデルにおけるコンテクスト依存的なNotch経路活性化の意義
2015 - 2017 肝上皮系細胞の分化を規定するマスタースイッチの探索
2014 - 2017 肝発癌に関わる癌遺伝子の腫瘍維持・進展における役割の検討
2012 - 2016 肝細胞と細胆管上皮の相互可塑性-細胆管反応における意義の解明と肝疾患治療への展開

Show all

Papers (56)：

Masanori Goto, Takako Ooshio, Masahiro Yamamoto, Hiroki Tanaka, Yumiko Fujii, Lingtong Meng, Yuki Kamikokura, Yoko Okada, Yuji Nishikawa. High levels of Myc expression are required for the robust proliferation of hepatocytes, but not for the sustained weak proliferation. Biochimica et biophysica acta. Molecular basis of disease. 2023. 1869. 4. 166644-166644
Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Masashi Okada, Chifumi Kitanaka. Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. Cancers. 2022. 14. 7
Masashi Okada, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Masahiro Yamamoto, Chifumi Kitanaka. Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts. International journal of molecular sciences. 2021. 22. 21
Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Shizuka Seino, Asuka Sugai, Takashi Yoshioka, Masashi Okada, Chifumi Kitanaka. Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin. Anticancer research. 2021. 41. 9. 4321-4331
Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Masashi Okada, Chifumi Kitanaka. Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction. Life (Basel, Switzerland). 2021. 11. 9

ｍore...

Lectures and oral presentations (2)：

新規抗がん幹細胞薬AS602801はサバイビンとMDR1の抑制を介して卵巣癌幹細胞のカルボプラチンとパクリタキセルへの感受性を高める(AS602801 chemosensitizes ovarian cancer stem cells to carboplatin and paclitaxel by suppressing survivin and MDR1)
(日本癌学会総会記事)
腹水細胞診に出現した卵巣顆粒膜細胞腫の1例
(日本臨床細胞学会雑誌 2018)

Education (2)：

2002 - 2006 Asahikawa Medical College Graduate School, Division of Medicine
1996 - 2002 Yamagata University Faculty of Medicine

Work history (5)：

2022/04 - 現在 Kumamoto University Department of Morphological and Physiological Sciences, Graduate School of Health Science Professor
2018/04 - 現在 Yamagata University Faculty of Medicine School of Medicine Department of Molecular Cancer Science Assistant Professor
2016/04 - 2018/03 Asahikawa Medical College Lecturer
2008/06 - 2016/03 Asahikawa Medical College Assistant Professor
2006/04 - 2008/05 Asahikawa Medical College Hospital Medical Staff

Awards (1)：

2016 - 肝細胞研究会肝細胞研究会ポスター賞

Association Membership(s) (5)：

病理学会 , 臨床細胞学会 , 肝細胞研究会 , 日本がん学会 , アメリカがん学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page